Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This ...
Septerna reports Q4 EPS (64c), consensus (69c)
Reports Q4 revenue $212,000, consensus $150,000. “Our Native Complex Platform continues to produce a deep pipeline of oral small molecule ...
C&EN20d
Fine-Tuned Deep Transfer Learning Models for Large Screenings of Safer Drugs Targeting Class A GPCRs
G protein-coupled receptors (GPCRs) remain a focal point of research due to their ... the attention that a research article has received online. Clicking on the donut icon will load a page at ...
C&EN29d
Biased GPCR Signaling: Possible Mechanisms and Therapeutic Applications
Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China Key ...
Nasdaq29d
RSI Alert: Structure Therapeutics (GPCR) Now Oversold
In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.